Navigation Links
Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
Date:10/22/2008

ated in an ongoing Phase 2 clinical trial in patients with metastatic hormone-refractory prostate cancer. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors. The oral formulation of picoplatin has the same active pharmaceutical ingredient as the intravenous formulation. Picoplatin has not been approved by any regulatory authority for use in humans.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. For additional information please visit http://www.poniard.com.

This release contains forward-looking statements, including statements regarding the Company's business objectives and strategic goals, drug development plans, timing and results of clinical trials and the potential safety and efficacy of its products in development. The Company's actual results may differ materially from those indicated in these forward-looking statements based on a number of factors, including risks and uncertainties associated with the Company's research and development activities; the results of pre-clinical and clinical testing; the receipt and timing of required regulatory approvals; the market's acceptance of the Company's proposed products; the Company's anticipated operating losses, need for future capital and ability to obtain future funding; competition from third parties; the Company's ability to preserve and protect intellectual property rights; the Company's dependence on third-party manufacturers and suppliers; the Company's lack of sales and marketing experience; the Company's ability to attract and retain key personnel; changes in technology, government regulation and general market conditions; and the risks and uncertainties described in the Company's current and periodic reports filed with the Securities and Exchan
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Poniard Pharmaceuticals Announces Upcoming Conference Participation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that Lionel Goldfrank ... succeed Donald Fresne ; Mr. Fresne has also resigned ... of the Board.  In recognition of the many contributions and ... twenty years, the Board designated Mr. Fresne as Chairman Emeritus. ... Search Committee to find a suitable replacement with Biotech industry ...
(Date:12/17/2014)... Based on the revenues gained ... market is dominated by four major players contributing ... These players include GE Healthcare (U.K.), Siemens AG ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... be attributed to its strong product portfolio, which ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... (Nasdaq: VRUS ), a clinical stage pharmaceutical ... to treat viral infections, reported financial results and operational ... Financial Results Revenues were $1.9 million during the ... for the quarter ended March 31, 2008 and reflect ...
... Iceland, May 11 deCODE genetics,(Nasdaq: DCGN ) ... March 31, 2009. A conference call to discuss these ... webcast live tomorrow,Tuesday, May 12, at 8:00am Eastern Daylight ... Net loss for the quarter ended ...
... MOUNTAIN VIEW, Calif., May 11 VIVUS, Inc. (Nasdaq: ... and commercialization of novel therapeutic products, today reported its highlights and ... First Quarter 2009 Highlights: , ... European Patent for Qnexa - In January 2009, we announced ...
Cached Biology Technology:Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 2Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 3Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 4Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 5Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 6Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 7Pharmasset Reports Fiscal Second Quarter 2009 Financial Results 8deCODE genetics Announces First Quarter 2009 Financial Results 2deCODE genetics Announces First Quarter 2009 Financial Results 3deCODE genetics Announces First Quarter 2009 Financial Results 4deCODE genetics Announces First Quarter 2009 Financial Results 5deCODE genetics Announces First Quarter 2009 Financial Results 6deCODE genetics Announces First Quarter 2009 Financial Results 7deCODE genetics Announces First Quarter 2009 Financial Results 8VIVUS Reports First Quarter 2009 Financial Results and Highlights 2VIVUS Reports First Quarter 2009 Financial Results and Highlights 3VIVUS Reports First Quarter 2009 Financial Results and Highlights 4VIVUS Reports First Quarter 2009 Financial Results and Highlights 5VIVUS Reports First Quarter 2009 Financial Results and Highlights 6VIVUS Reports First Quarter 2009 Financial Results and Highlights 7
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
(Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
Breaking Biology News(10 mins):Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... A molecule that helps the body's motor nerve cells ... a major role in inhibiting spinal-cord neurons from regenerating ... found. In cultured cells, the researchers found that a ... stabilizes long nerve fibers in adult vertebrates ?chemically blocks ...
... researchers first to report function of tunneling nanotubules , ... an extensive network of tiny tunnels that, like a ... signals to distant cells. This surprising discovery, being reported ... in the September issue of the journal Immunity, may ...
... seeking ways to eliminate pollution from waterways with microbes ... freshwater ponds can generate electricity. They present their findings ... Society for Microbiology. , "The bacteria are capable of ... to operate small electronic devices. As long as the ...
Cached Biology News:Researchers find molecule that inhibits regrowth of spinal nerve cells 2Researchers find molecule that inhibits regrowth of spinal nerve cells 3'Underground' tunnels discovered as means for communication between immune system cells 2'Underground' tunnels discovered as means for communication between immune system cells 3'Underground' tunnels discovered as means for communication between immune system cells 4Pollution-eating bacteria produce electricity 2
... siRNA library screening, optimal siRNA ... and verified for each cell ... siRNA Transfection Optimization Kit, which ... transfection conditions in 96 well ...
... Series of positioning slides offers multiple ... leadscrew, micrometer, and manual. With this ... cost-effective multi-axis systems. These slides also ... resolutions down to 10 nanometers, integrated ...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
Kit Components: Anti-PARP LumiGLO Chemiluminescent Substrate Immunoblot Blocking Reagent Pyronin Y Reagent Goat Anti-Rabbit IgG, HRP conjugate Double-It Reagent Film Exposure Folders Autor...
Biology Products: